Display options
Cite
Marvanova M. Pharmacokinetic characteristics of antiepileptic drugs (AEDs). Ment Health Clin. 2016;6(1):8-20doi: 10.9740/mhc.2015.01.008.
Marvanova, M. (2016). Pharmacokinetic characteristics of antiepileptic drugs (AEDs). The mental health clinician, 6(1), 8-20. https://doi.org/10.9740/mhc.2015.01.008
Marvanova, Marketa. "Pharmacokinetic characteristics of antiepileptic drugs (AEDs)." The mental health clinician vol. 6,1 (2016): 8-20. doi: https://doi.org/10.9740/mhc.2015.01.008
Marvanova M. Pharmacokinetic characteristics of antiepileptic drugs (AEDs). Ment Health Clin. 2016 Mar 08;6(1):8-20. doi: 10.9740/mhc.2015.01.008. eCollection 2016 Jan. PMID: 29955442; PMCID: PMC6009244.
Copy Download .nbib Format: NLM
Share it on

Ment Health Clin. 2016 Mar 08;6(1):8-20. doi: 10.9740/mhc.2015.01.008. eCollection 2016 Jan.

Pharmacokinetic characteristics of antiepileptic drugs (AEDs).

The mental health clinician

Marketa Marvanova

Affiliations

  1. Chair and Associate Professor, College of Health Professions, School of Pharmacy, North Dakota State University, Fargo, North Dakota,[email protected].

PMID: 29955442 PMCID: PMC6009244 DOI: 10.9740/mhc.2015.01.008

Abstract

Antiepileptic drugs (AEDs) are routinely prescribed for the management of a variety of neurologic and psychiatric conditions, including epilepsy and epilepsy syndromes. Physiologic changes due to aging, pregnancy, nutritional status, drug interactions, and diseases (ie, those involving liver and kidney function) can affect pharmacokinetics of AEDs. This review discusses foundational pharmacokinetic characteristics of AEDs currently available in the United States, including clobazam but excluding the other benzodiazepines. Commonalities of pharmacokinetic properties of AEDs are discussed in detail. Important differences among AEDs and clinically relevant pharmacokinetic interactions in absorption, distribution, metabolism, and/or elimination associated with AEDs are highlighted. In general, newer AEDs have more predictable kinetics and lower risks for drug interactions. This is because many are minimally or not bound to serum proteins, are primarily renally cleared or metabolized by non-cytochrome P450 isoenzymes, and/or have lower potential to induce/inhibit various hepatic enzyme systems. A clear understanding of the pharmacokinetic properties of individual AEDs is essential in creating a safe and effective treatment plan for a patient.

Keywords: CYP450; UGT; antiepileptic drugs; hepatic metabolism; pharmacokinetic interactions; protein binding

References

  1. Curr Neuropharmacol. 2010 Sep;8(3):254-67 - PubMed
  2. Clin Pharmacokinet. 2006;45(11):1061-75 - PubMed
  3. Epileptic Disord. 2004 Jun;6(2):57-75 - PubMed
  4. Clin Neuropharmacol. 2003 Jan-Feb;26(1):38-52 - PubMed
  5. Br J Clin Pharmacol. 2006 Mar;61(3):246-55 - PubMed
  6. Pharmaceuticals (Basel). 2010 Jun 11;3(6):1909-1935 - PubMed
  7. Acta Neurol Scand. 2004 Jun;109(6):374-7 - PubMed
  8. Drug Metab Pharmacokinet. 2012;27(2):248-54 - PubMed
  9. Clin Pharmacokinet. 2013 Nov;52(11):927-66 - PubMed
  10. Neurology. 2002 Jul 23;59(2):251-5 - PubMed
  11. Clin Pharmacokinet. 2014 Jan;53(1):29-49 - PubMed
  12. Neurology. 2003 Aug 26;61(4):570-1 - PubMed
  13. Nutr Clin Pract. 1996 Feb;11(1):28-31 - PubMed
  14. Pharmacotherapy. 2008 Nov;28(11):1391-400 - PubMed
  15. Epilepsia. 2004;45 Suppl 6:28-34 - PubMed
  16. Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):301-19 - PubMed
  17. Clin Pharmacokinet. 2002;41(8):559-79 - PubMed
  18. Biochem Pharmacol. 1994 Jun 1;47(11):1969-79 - PubMed
  19. Pharm Res. 1993 Feb;10(2):276-81 - PubMed
  20. Seizure. 2013 Sep;22(7):528-36 - PubMed
  21. J Clin Pharmacol. 2008 Dec;48(12):1378-88 - PubMed
  22. Epilepsia. 2008 Jul;49(7):1123-41 - PubMed
  23. Epilepsia. 2013 Jan;54(1):108-16 - PubMed
  24. Epilepsy Res. 2003 Dec;57(2-3):85-93 - PubMed
  25. Epilepsia. 2012 Jun;53(6):935-46 - PubMed
  26. Ann Pharmacother. 2000 Jul-Aug;34(7-8):896-905 - PubMed
  27. Epilepsy Behav. 2015 Jan;42:7-9 - PubMed
  28. Epilepsy Curr. 2009 Nov-Dec;9(6):153-7 - PubMed
  29. Clin Pharmacokinet. 2013 Aug;52(8):627-45 - PubMed
  30. Ther Drug Monit. 1999 Apr;21(2):175-81 - PubMed
  31. Clin Pharmacol Ther. 1999 Dec;66(6):547-53 - PubMed
  32. Mol Pharmacol. 2002 Apr;61(4):729-37 - PubMed
  33. Drug Metab Rev. 1976;5(1):43-140 - PubMed

Publication Types